List view / Grid view
The World Health Organization (WHO) asserts that vaccines could reduce…
The World Health Organization (WHO) asserts that vaccines could reduce antibiotic use as well as economic costs of antimicrobial resistance (AMR) worldwide.
This article discusses the impact of the recent mpox emergency…
This article discusses the impact of the recent mpox emergency following the outbreak of the virus in 2022, highlights the industry’s response, potential vaccine candidates and key recommendations for international management of the disease.
Expansion of the WLA framework means that the largest number…
Expansion of the WLA framework means that the largest number of regulatory agencies for medical products are approved as WHO Listed Authorities.
The new industry collaboration aims to help decarbonise the global…
The new industry collaboration aims to help decarbonise the global supply chain by focusing on the energy-intensive pharmaceutical manufacturing that takes place in China and India.
WHO’s Global Antimicrobial Resistance and Use Surveillance System (GLASS) report…
WHO’s Global Antimicrobial Resistance and Use Surveillance System (GLASS) report 2022 contains AMR trends for the first time since 2017.
A 2022 WHO report is the first to portray COVID-19’s…
A 2022 WHO report is the first to portray COVID-19’s impact on the global vaccine market, identifying that lower-income countries struggle to access critical vaccines.
In a global first, the health sector has converged to…
In a global first, the health sector has converged to incentivise supply chains and clinical trials to reduce emissions through the Sustainable Markets Initiative Health Systems Task Force.
In this article, EPR’s Hannah Balfour discusses the recent multi-country…
In this article, EPR’s Hannah Balfour discusses the recent multi-country monkeypox outbreak, highlighting key developments in the international response.
New global alliance launched by UNAIDS, UNICEF and WHO aims…
New global alliance launched by UNAIDS, UNICEF and WHO aims to overcome “outrageous” disparities in the AIDS response and ultimately end AIDS in children by 2030.
In this final article on the TRIPS waiver for COVID-19…
In this final article on the TRIPS waiver for COVID-19 vaccines, medicines, diagnostics and technologies, EPR’s Hannah Balfour considers whether it is the correct strategy to overcome COVID-19 treatment inequalities and explores other options.
To promote the safe and ethical use of genome editing…
To promote the safe and ethical use of genome editing for the treatment of disease and genetic disorders WHO has published the first global recommendations.
A South African consortium will be the first to establish…
A South African consortium will be the first to establish a COVID-19 mRNA vaccine technology transfer hub to scale up vaccine production and access.
Global leaders at the G7 summit pledged 870 million COVID-19…
Global leaders at the G7 summit pledged 870 million COVID-19 vaccine doses, with half to be delivered by the end of 2021, to COVAX for distribution among low- and middle-income countries.
South Africa and India’s request that the World Trade Organization…
South Africa and India’s request that the World Trade Organization waive intellectually property rights for COVID-19 vaccines, treatments, diagnostics and technology has garnered extensive media coverage, particularly since the US decision to support the proposal. In a three-part series, European Pharmaceutical Review’s Assistant Editor, Hannah Balfour, will discuss the IP…
The COVAX No-fault Compensation Program will offer individuals in 92…
The COVAX No-fault Compensation Program will offer individuals in 92 lower-income countries and economies compensation for serious adverse events associated with COVID-19 vaccines distributed through COVAX.
